Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-ASSURE trial in severe systemic sclerosis
ACTRN12623000292673Phase 2Recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide, rituximab, antithymocyte globulin rabbit and filgrastim in systemic sclerosis (SSc) (4 cohorts), sponsored by St Vincent's Hospital. Primary endpoints: Transplant-related mortality in standard-dose arm and Transplant-related mortality in low-dose arm. Started Aug 2023; status: recruiting.
02
Drugs
cyclophosphamiderituximabantithymocyte globulin rabbitfilgrastim
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on ACTRN12623000292673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000292673.